---
schema_version: "secwatch.filing_event.v1"
accession: "0001683168-25-005392"
form_type: "8-K"
ticker: "PHIO"
cik: "0001533040"
company_name: "Phio Pharmaceuticals Corp."
filed_at: "2025-07-25T23:59:59+00:00"
generated_at: "2026-05-18T01:07:27.701528+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Phio reports complete response in cSCC and manufacturing agreement for PH-762

## Summary
- Entered into comprehensive drug substance development agreement with U.S. manufacturer for PH-762.
- Phase 1b fourth-cohort: one complete pathologic response (100% tumor clearance) in cSCC patient.
- One partial response (>50% clearance) in stage 4 metastatic Merkel cell; two non-responses in cSCC.
- No dose-limiting toxicities; PH-762 well tolerated across all cohorts; no clinical progression.
- Enrolling 5th and expected final cohort in Phase 1b dose escalation study for cutaneous carcinomas.

## SEC filing metadata
- accession: 0001683168-25-005392
- form_type: 8-K
- ticker: PHIO
- cik: 0001533040
- company_name: Phio Pharmaceuticals Corp.
- filed_at: 2025-07-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1533040/000168316825005392/0001683168-25-005392-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1533040/000168316825005392/phio_8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001683168-25-005392
- JSON: https://secwatch.observer/filing/0001683168-25-005392.json
- Plain text: https://secwatch.observer/filing/0001683168-25-005392.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.